Peptide RX

back to claim graph

proof receipt / fold

SIRT1 WT

Structure prediction with public confidence context.

grade B status complete receipt 50209d6ccaf2 proof 67%

what this node claims

SIRT1 WT

Structure prediction with public confidence context.

Open source surface

vertical proof spine

  1. 01 SIRT1 WT fold / grade B / 54% 3 debt
  2. 02 AlphaFold metrics / SIRT1 alphafold metric / grade B / 70% 1 debt
  3. 03 Initial digest — SIRT1 finding / grade C / 47% 1 debt
  4. 04 fold.complete timeline event / grade C / 55%
  5. 05 SIRT1 target / grade B / 70% 1 debt

evidence / risk instrument

47%
thin proof
structure evidence gates risk export lineage 47
visible debt pressure 50%
65%structureusable
pLDDT 65.02
55%evidencethin
grade C
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
67%lineageusable
incomplete spine

proof completeness

67% missing candidate, export
  1. 01 target
  2. 02 fold
  3. 03 alphafold metric
  4. 04 candidate
  5. 05 finding
  6. 06 export

Metrics and receipt inputs

confidence band
low
confidence pct
65.02
coverage available
false
gene
SIRT1
has structure
true
pae available
false
plddt avg
65.02
sequence length
0
variant
WT

AlphaFold metrics visual

Low-confidence regions present

65.0

747 residues / min 24.66 / max 98.88 / source alphafold db

PAE matrix for linked target
Very high 36.9% 276 residues / >=90
Confident 13.0% 97 residues / 70-89
Low 3.5% 26 residues / 50-69
Very low 46.6% 348 residues / <50

weak structural context; downstream claims should be conservative

Near-complete coverage / observed 747 of 747 residues.

  • residues 1-148 / mean 37.74
  • residues 517-630 / mean 36.16
  • residues 660-747 / mean 37.45
  • residues 155-177 / mean 48.56
proof debt register

Visible limits, not hidden cleanup.

50%

Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.

low computational-only status add independent evidence, challenge result, or witness review before strengthening
low low-confidence AlphaFold regions likely attach pLDDT series, PAE matrix, or coverage evidence
medium no candidate yet leave visible until a stronger public receipt resolves it
medium missing PAE/context where AlphaFold DB is not linked attach pLDDT series, PAE matrix, or coverage evidence
high low evidence grade attach graded finding with source-linked evidence
medium missing functional-site annotations link target annotation, GO term, or binding-site context

weakness and challenge edges

What would stop this from becoming stronger.

debt severity export claim strength next proof needed
computational-only status low visible watch add independent evidence, challenge result, or witness review before strengthening
low-confidence AlphaFold regions likely low visible watch attach pLDDT series, PAE matrix, or coverage evidence
no candidate yet medium visible weakens leave visible until a stronger public receipt resolves it
missing PAE/context where AlphaFold DB is not linked medium visible weakens attach pLDDT series, PAE matrix, or coverage evidence
low evidence grade high blocks weakens attach graded finding with source-linked evidence
missing functional-site annotations medium visible weakens link target annotation, GO term, or binding-site context

what supports it

target has structure prediction target:1dbe24d9-c749-41b4-b88b-0046388348b5 -> fold:39c8f542-5bfc-4743-bd9d-2e14ab2e3c2f folds_to / B / 0.65

what it supports

measured by AlphaFold confidence context fold:39c8f542-5bfc-4743-bd9d-2e14ab2e3c2f -> alphafold_metric:39c8f542-5bfc-4743-bd9d-2e14ab2e3c2f measured_by / B / 0.65
evidence finding attached fold:39c8f542-5bfc-4743-bd9d-2e14ab2e3c2f -> finding:ed412e33-c09b-4de5-b1b6-33541d690ed0 supports / C / 0.6
timeline records state change fold:39c8f542-5bfc-4743-bd9d-2e14ab2e3c2f -> timeline_event:28 records / C / 0.5

Research-use boundary

This receipt describes public computational research state. It does not expose raw candidate sequences and does not make a clinical claim.